These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12437503)

  • 41. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
    J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide.
    Kalsi JS; Ralph DJ; Thomas P; Bellringer J; Minhas S; Kell PD; Cellek S
    J Sex Med; 2005 Jan; 2(1):53-7. PubMed ID: 16422907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
    Gibson A
    Eur J Pharmacol; 2001 Jan; 411(1-2):1-10. PubMed ID: 11137852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
    Jacobsohn K; Wang R
    Asian J Androl; 2007 Jan; 9(1):3-7. PubMed ID: 17187154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
    Seftel AD
    Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
    Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
    Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats.
    Wilkes N; White S; Stein P; Bernie J; Rajasekaran M
    Int J Impot Res; 2004 Apr; 16(2):187-94. PubMed ID: 15073608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Chronic treatment with PDE-5 inhibitors is there anything more than treating erectile dysfunction?].
    Vela Navarrete R; García Cardoso JV; López Farre A; Quesada Romero P; Pardo Montero M
    Actas Urol Esp; 2007 Mar; 31(3):179-84. PubMed ID: 17658146
    [No Abstract]   [Full Text] [Related]  

  • 49. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of nitric oxide-sensitive guanylyl cyclase.
    Friebe A; Koesling D
    Circ Res; 2003 Jul; 93(2):96-105. PubMed ID: 12881475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.
    Nagayama T; Zhang M; Hsu S; Takimoto E; Kass DA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):380-7. PubMed ID: 18456872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.
    Eisenhardt A; Sperling H; Hauck E; Porst H; Stief C; Rübben H; Müller N; Siffert W
    Urology; 2003 Jul; 62(1):152-7. PubMed ID: 12837457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unexpected insights into pelvic function following phosphodiesterase manipulation--what's next for urology?
    McVary KT
    Eur Urol; 2006 Dec; 50(6):1153-6. PubMed ID: 17045387
    [No Abstract]   [Full Text] [Related]  

  • 54. Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception.
    Patil CS; Jain NK; Singh VP; Kulkarni SK
    Indian J Exp Biol; 2004 Apr; 42(4):361-7. PubMed ID: 15088685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 56. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
    Filippi S; Morelli A; Sandner P; Fibbi B; Mancina R; Marini M; Gacci M; Vignozzi L; Vannelli GB; Carini M; Forti G; Maggi M
    Endocrinology; 2007 Mar; 148(3):1019-29. PubMed ID: 17138653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.
    Pauvert O; Lugnier C; Keravis T; Marthan R; Rousseau E; Savineau JP
    Br J Pharmacol; 2003 Jun; 139(3):513-22. PubMed ID: 12788811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.
    Mullershausen F; Russwurm M; Koesling D; Friebe A
    Mol Biol Cell; 2004 Sep; 15(9):4023-30. PubMed ID: 15240816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular mechanisms of the effects of sildenafil (VIAGRA).
    Glossmann H; Petrischor G; Bartsch G
    Exp Gerontol; 1999 Jun; 34(3):305-18. PubMed ID: 10433386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
    Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.